HomeCompareATEPF vs JNJ

ATEPF vs JNJ: Dividend Comparison 2026

ATEPF yields 363.83% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATEPF wins by $5766.09M in total portfolio value
10 years
ATEPF
ATEPF
● Live price
363.83%
Share price
$0.55
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5766.11M
Annual income
$3,742,597,980.41
Full ATEPF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ATEPF vs JNJ

📍 ATEPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATEPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATEPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATEPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATEPF
Annual income on $10K today (after 15% tax)
$30,925.96/yr
After 10yr DRIP, annual income (after tax)
$3,181,208,283.35/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ATEPF beats the other by $3,181,207,579.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATEPF + JNJ for your $10,000?

ATEPF: 50%JNJ: 50%
100% JNJ50/50100% ATEPF
Portfolio after 10yr
$2883.07M
Annual income
$1,871,299,404.09/yr
Blended yield
64.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ATEPF
No analyst data
Altman Z
236.5
Piotroski
0/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATEPF buys
0
JNJ buys
0
No recent congressional trades found for ATEPF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATEPFJNJ
Forward yield363.83%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$5766.11M$20.0K
Annual income after 10y$3,742,597,980.41$827.78
Total dividends collected$5574.88M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ATEPF vs JNJ ($10,000, DRIP)

YearATEPF PortfolioATEPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$47,083$36,383.48$10,676$355.77+$36.4KATEPF
2$210,478$160,099.16$11,407$389.39+$199.1KATEPF
3$894,086$668,874.15$12,198$426.53+$881.9KATEPF
4$3,612,086$2,655,414.27$13,056$467.62+$3.60MATEPF
5$13,890,923$10,025,990.33$13,987$513.12+$13.88MATEPF
6$50,897,619$36,034,331.38$14,998$563.56+$50.88MATEPF
7$177,855,877$123,395,424.73$16,098$619.52+$177.84MATEPF
8$593,288,147$402,982,359.06$17,295$681.69+$593.27MATEPF
9$1,891,136,685$1,256,318,367.62$18,599$750.82+$1891.12MATEPF
10$5,766,114,234$3,742,597,980.41$20,022$827.78+$5766.09MATEPF

ATEPF vs JNJ: Complete Analysis 2026

ATEPFStock

Astra Exploration Inc., an exploration company, engages in the acquisition, exploration, and development of epithermal gold-silver properties in Chile. It holds 80% interest in the Pampa Paciencia project located in the Antofagasta Region of Chile. The company is headquartered in Vancouver, Canada.

Full ATEPF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ATEPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATEPF vs SCHDATEPF vs JEPIATEPF vs OATEPF vs KOATEPF vs MAINATEPF vs ABBVATEPF vs MRKATEPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.